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ABSTRACT Routine full characterization of Mycobacterium tuberculosis is culture
based, taking many weeks. Whole-genome sequencing (WGS) can generate antibi-
otic susceptibility proﬁles to inform treatment, augmented with strain information
for global surveillance; such data could be transformative if provided at or near the
point of care. We demonstrate a low-cost method of DNA extraction directly from
patient samples for M. tuberculosis WGS. We initially evaluated the method by using
the Illumina MiSeq sequencer (40 smear-positive respiratory samples obtained after
routine clinical testing and 27 matched liquid cultures). M. tuberculosis was identiﬁed
in all 39 samples from which DNA was successfully extracted. Sufﬁcient data for anti-
biotic susceptibility prediction were obtained from 24 (62%) samples; all results were
concordant with reference laboratory phenotypes. Phylogenetic placement was con-
cordant between direct and cultured samples. With Illumina MiSeq/MiniSeq, the
workﬂow from patient sample to results can be completed in 44/16 h at a reagent
cost of £96/£198 per sample. We then employed a nonspeciﬁc PCR-based library
preparation method for sequencing on an Oxford Nanopore Technologies MinION
sequencer. We applied this to cultured Mycobacterium bovis strain BCG DNA and to
combined culture-negative sputum DNA and BCG DNA. For ﬂow cell version R9.4,
the estimated turnaround time from patient to identiﬁcation of BCG, detection of
pyrazinamide resistance, and phylogenetic placement was 7.5 h, with full susceptibil-
ity results 5 h later. Antibiotic susceptibility predictions were fully concordant. A crit-
ical advantage of MinION is the ability to continue sequencing until sufﬁcient cover-
age is obtained, providing a potential solution to the problem of variable amounts
of M. tuberculosis DNA in direct samples.
KEYWORDS DNA sequencing, Mycobacterium tuberculosis, antibiotic resistance,
diagnostics
The long-standing gold standard for Mycobacterium tuberculosis drug susceptibilitytesting (DST) is the phenotypic culture-based approach, which is time-consuming
and laborious. First-line tuberculosis (TB) treatment includes four drugs (rifampin,
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isoniazid, ethambutol, and pyrazinamide), but with the spread of multidrug-resistant
strains, there is a growing need for data on second-line drugs, including the ﬂuoro-
quinolones and aminoglycosides.
Because of the long turnaround times for phenotypic testing (up to 2 months),
it is often preceded by WHO-endorsed molecular methods such as the GenoType
MTBDRplus and MTBDRsl assays (Hain Lifescience GmbH, Germany) and Xpert
MTB/RIF (Cepheid, USA). These potentially culture-free, PCR-based tests rapidly identify
isolates to the species level and detect the most common drug resistance-conferring
mutations. However, this technology is limited by the number of mutations that can be
probed. This limitation is of concern, given the many low-frequency drug resistance-
conferring mutations inM. tuberculosis, particularly for second-line drugs (1). Consistent
with this concern, the proportion of phenotypically resistant samples that are detect-
able by MTBDRplus ranges from 21 to 25% for the second-line drugs capreomycin and
kanamycin (2) to 98.4% and 91.4% for the critical ﬁrst-line drugs rifampin and isoniazid
(3). A potential solution is to sequence amplicons targeting a wider range of resistance-
conferring genes, as previously demonstrated (4).
The potential of whole-genome sequencing (WGS) as a diagnostic assay has been
repeatedly identiﬁed (5–7). Recent studies based on WGS of mycobacteria have eval-
uated WGS-based susceptibility predictions (1, 8–10), species identiﬁcation, and eluci-
dation of epidemiology (11–16). This has culminated in the ﬁrst successful application
of WGS as a clinical diagnostic for mycobacteria from early positive liquid cultures (16).
Moreover, WGS was performed at a cost comparable to that of existing phenotypic
assays and offered shorter turnaround times.
Generating WGS information directly from patient samples and avoiding the
need for culture would be transformative. However, direct samples contain highly
variable amounts of mycobacterial cells mixed with other bacterial and human cells,
with the latter accounting for up to 99.9% of the DNA present. Furthermore,
mycobacterial cells may aggregate because of the high mucus content of some
samples, meaning that the sample volume and acid-fast bacillus (AFB) count may
not represent the total quantity of mycobacteria available. Direct samples therefore
require preprocessing to homogenize and enrich for mycobacteria by depleting
other cells/DNA. The challenges of direct sample processing were illustrated by two
studies assessing the feasibility of direct WGS of clinical samples (17, 18). By
sequencing eight smear-positive sputum samples subjected to differential lysis
followed by DNA extraction with a commercial kit, Doughty and colleagues were
able to achieve only a 0.002 to 0.7 depth of coverage for M. tuberculosis, with
20.3 to 99.3% of the sequences mapping to the human genome. Seven of eight
samples could be assigned to the M. tuberculosis complex, but none had sufﬁcient
data for drug susceptibility prediction. In a second study, Brown and colleagues
applied a SureSelect target enrichment method (Agilent, USA) to capture M.
tuberculosis DNA prior to WGS. Twenty of 24 smear-positive samples achieved 90%
genome coverage with 20 depth, sufﬁcient for prediction of species and
antibiotic susceptibility. However, the protocol was slow (2 to 3 days) and may be
prohibitively expensive for use in low-income settings.
In this study, we tested a simple, low-cost DNA extraction method using Illumina
MiSeq for WGS of 40 smear-positive, primary respiratory samples from M. tuberculosis-
infected patients. We evaluated the protocol in terms of the DNA obtained, the species
assignment of the sequenced reads, and our ability to obtain key clinical data (detec-
tion of M. tuberculosis and antibiotic susceptibility prediction) along with epidemiolog-
ical information (placement on a phylogenetic tree). These data would enable a single
test to deliver the core information for both patient and public health in48 h by using
Illumina-based WGS. We also developed an approach for WGS by using the highly
portable, random-access, Oxford Nanopore Technologies (ONT) MinION, reducing the
potential turnaround time to 12 h.
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RESULTS
DNA extraction protocol and evaluation of Illumina sequencing output. DNA
was extracted from 40 Ziehl-Neelsen (ZN)-positive direct respiratory samples, of which
38 were culture conﬁrmed M. tuberculosis positive (culture positive) and 2 were culture
negative. DNA was also extracted from 28 available corresponding mycobacterial
growth indicator tube (MGIT) cultures. All direct samples were the remainders of
specimens available after processing by the routine laboratory and therefore had
various volumes (median, 1.5 ml; interquartile range [IQR], 0.5 to 3.1 ml; range, 0.25 to
15 ml) and age (median, 30 days from collection to processing; IQR, 15 to 45 days;
range, 0 to 67 days). Most direct samples (78%; 31/40) could therefore be considered
suboptimal on the basis of a low volume (1 ml), a long storage time (30 days), or
both.
After DNA extraction, 33/40 (83%) direct samples and all 28 MGIT cultures
yielded 0.2 ng/l DNA, the amount recommended for MiSeq Illumina library
preparation (Fig. 1).
There was no evidence that the DNA yield was affected (in either multivariable or
univariable models) by (i) the sample type (sputum or bronchoalveolar lavage ﬂuid)
(P  0.94; univariable linear regression), (ii) AFB scoring (from 1 to 3) (P  0.56), (iii)
the storage time prior to DNA extraction (days from collection) (P  0.51), or (iv) the
sample volume (P  0.28). Although the DNA concentration was measured and
recorded after extraction, further data on DNA quality (e.g., the DNA integrity number
[DIN] provided by TapeStation [Agilent, USA]) were not routinely recorded.
In total, 39/40 direct samples with detectable DNA (37 culture positive, 2 culture
negative) and 27/28 MGIT cultures were sequenced with Illumina MiSeq. One MGIT
culture was not sequenced because the corresponding direct sample failed to yield
measurable DNA. We used a lower-than-recommended DNA concentration threshold
for MiSeq library preparation (0.05 ng/l rather than 0.2 ng/l) on the basis of
previous experience with the sequencing of mycobacterial cultures with suboptimal
amounts of DNA (19). Six (15%) of 40 samples yielded DNA below the 0.2-ng/l
threshold. All sequenced direct samples produced 1.5 million reads (median, 3.6
million; IQR, 2.9 to 5.0 million; range, 1.5 to 12 million), as did all MGIT cultures (median,
3.1 million; IQR, 2.8 to 3.3 million; range, 2.0 to 4.1 million).
Contamination levels of direct and MGIT samples. We assigned reads to the
categories M. tuberculosis, human, nasopharyngeal ﬂora (NPF), and other by mapping
(see Materials and Methods). Seventy-seven percent (30/39) of the direct samples
contained 10% human reads. However, only 46% (18/39) contained 10% NPF and
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FIG 1 Concentrations of DNA extracted from MGIT cultures and direct clinical samples. Each dot
represents a single extraction. The horizontal line at 0.2 ng/l represents the DNA concentration
theoretically required for MiSeq library preparation. The horizontal line at 0.05 ng/l represents the
minimum DNA concentration used for MiSeq library preparation from direct samples in this study. One
sample not shown as DNA was below the limit of detection.
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other bacterial reads, and 26% (10/39) contained 40% reads from nonmycobacterial,
non-NPF, bacteria (Fig. 2a). In comparison, MGIT culture samples showed much less
contamination, as expected (Fig. 2b).
Recovery of M. tuberculosis genome. Figure 3a shows the distribution of the M.
tuberculosis reference genome depth of coverage across direct samples. Twenty-one of
39 samples have 12 depth and recover 90% of the genome, and 14/39 samples
have 3 depth and recover 12% of the genome. The vertical dotted line delineates
our threshold of 3 coverage, below which resistance predictions were not made.
Figure 3b shows the amount of contamination (reads not mapping to M. tuberculosis)
per sample. Ten samples had 15% contaminant reads, although contamination levels
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FIG 2 Proportions of reads assigned to various species categories in each sample sorted by increasing total counts of M.
tuberculosis complex (MTBC) reads. (a) Direct samples show that removal of human DNA (red) has been broadly successful, but
removal of NPF (green) and other bacteria (purple) had more variable success. (b) MGIT samples show much more uniform
dominance of M. tuberculosis reads, as expected after 2 weeks of culture designed to favor mycobacterial growth.
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FIG 3 Recovery of M. tuberculosis genome in direct samples and robustness to contamination. (a) Depth versus proportion of the
M. tuberculosis reference recovered (at 5 depth). The vertical dotted line at 3 depth is the threshold used for resistance prediction in
this study. (b) Proportion of contamination (reads not mapping toM. tuberculosis reference) versus proportion of genome recovered. Samples
with 95% of the M. tuberculosis genome recovered all have 75% contaminated reads.
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increased as high as 75% before the proportion of the M. tuberculosis genome recov-
ered started to drop. Low numbers of M. tuberculosis reads could also reﬂect poor DNA
quality from samples stored for long periods, as most of the samples with 80%
reference genome coverage (12/17, 71%) were 3 weeks old before extraction.
Concordance of results from direct and MGIT samples. We took a set of 68,695
high quality single-nucleotide polymorphisms (SNPs) obtained from an analysis of 3,480
samples (1) and genotyped all of the samples at these positions (see Materials and
Methods). This allowed us to calculate the genetic distance between the 17 paired MGIT
and direct samples (after excluding 10 pairs where the direct sample had 5
coverage, to avoid systematic undercalling in direct samples). The median (and modal)
SNP difference was 1 (Fig. 4a), with one outlier pair of samples that differed by 1,106
SNPS (discussed below), and all other differences were 22 SNPs.
We placed 17 paired direct and MGIT samples on the phylogenetic tree from
reference 1 (see Materials and Methods). Our samples were distributed across global
diversity (Fig. 4b; tree thinned to aid visibility). For the pair with 1,106 SNP differences,
the direct sample was isolated on the tree but the MGIT sample was placed very closely
to three other pairs (0 SNP difference from one MGIT sample, and 5 SNP differences
from the others). Although this might result from different strains being present within
the host, a within-laboratory labeling error or cross-contamination is also possible.
No evidence of higher diversity in direct samples. Comparing direct/MGIT pairs
where both samples had at least a 20 mean depth of coverage on the M. tuberculosis
reference, the median number of high-conﬁdence (see Materials and Methods)
heterozygous sites was 25 in both direct and MGIT samples. There was no clear trend
of greater genome-wide diversity in direct samples (see Fig. S1 in the supplemental
material).
Detection ofM. tuberculosis in culture positive/negative samples. All sequenced
culture-positive (37/39) direct M. tuberculosis samples were successfully identiﬁed by
Mykrobe predictor to complex level (37/37) and 95% to species level (35/37), including
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FIG 4 Genotypic concordance between direct and paired MGIT samples. (a) Histogram of genetic (SNP) differences, excluding the one pair that differ by 1,106
SNPs; the median (and modal) difference is 1, and thus, direct sequencing is identifying the same strain of M. tuberculosis that culture-based sequencing would.
(b) Placing direct/MGIT pairs on a phylogenetic tree of 3,480 samples shows the distribution of samples across world diversity. A circle indicates the sequence
from the direct sample, and an X indicates the sequence from the corresponding MGIT sample. For the 1 pair (of 17) with 1,106 differences (turquoise), the
MGIT sample is placed very close to the other samples (zero SNP differences from one [MGIT] sample and ﬁve SNP differences from the others) and so is possibly
due to a labeling error.
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13/37 (35%) where the mean depth of coverage was 3. All MGIT cultures were
identiﬁed as M. tuberculosis. We were also able to identify M. tuberculosis in two of two
direct samples with low AFB scores (1) and no growth in MGIT culture; these may
represent dead bacilli from a patient undergoing treatment.
Antibiotic resistance prediction. In total, 168 predictions for ﬁrst-line (n  96) and
second-line (n  72) antibiotic susceptibility were made for the 24/37 (65%) direct
samples that had at least 3 depth (see Tables S1 and S2). For the 13/37 (35%) samples
that had 3 depth, no resistance predictions were made. This included one of two
culture-negative samples.
Ninety-two (96%) of 96 predictions for the ﬁrst-line antibiotics were concordant with
reference laboratory DST. The four mismatches (three pyrazinamide mixed genotypes
with both R and S alleles present and one rifampin-resistant genotype with a sensitive
phenotype) were found across three samples, all from the same patient (patient 2 in
Table S2), that had a variable phenotype for rifampin and pyrazinamide. The resistant
genotype for rifampin was consistent across all three samples from this patient
(rpoB_I491F). There is evidence that this mutation causes resistance but that the
phenotype is often reported as sensitive (1, 20, 21). The mixed genotype for pyrazi-
namide was again consistent with the presence of both R and S alleles on pncA_V7L
across all three samples, whereas the phenotype varied. This mutation is also known
to confer resistance in samples reported as phenotypically sensitive (1). Further, one
of three samples from this patient (602112 in Table S2) contained two additional
mutations conferring resistance to isoniazid and pyrazinamide, katG_S315T and
pncA_T135P, respectively, which were not detected in the previous or following
sample. This variation between genotypes from same-patient samples taken over
time may represent ongoing evolution, changing population size, and within-
patient diversity of M. tuberculosis, as previously demonstrated by Eldholm et al.
(22). In addition to the above, WGS provided 72 predictions for second-line anti-
biotics where DST was not attempted.
The 13/37 samples that yielded insufﬁcient WGS data for resistance prediction had
a higher proportion of other bacterial DNA (Fig. 3b, a median of 96% and an IQR of 38
to 70% versus a median of 12% and an IQR of 0 to 67% in those where resistance
prediction was possible [rank sum P  0.01]).
Sub-24-h turnaround time with Illumina MiniSeq. Illumina MiniSeq sequencing
of three samples (single run; one pure BCG DNA, two negative sputum DNA spiked with
BCG DNA) was completed in 6 h 40 min. The BCG reference genome coverage was 31
to 33 in spiked samples and 84 in pure BCG DNA (Table 1). In all cases, the
species/strain was correctly identiﬁed as M. bovis BCG and pyrazinamide resistance was
correctly identiﬁed because of an H57D mutation in pncA.
Modiﬁed method for ONT MinION. A new PCR-based rapid 1D MinION protocol
was tested by using extracted BCG DNA, ZN-negative sputum DNA spiked with BCG
DNA, and R9 ﬂow cells (see Materials and Methods). Analysis of genome-wide coverage
distribution conﬁrmed that use of PCR had not led to signiﬁcant coverage bias (see Fig.
S2) and that 95% of the reference genome attained coverage 5 for all samples. In
all cases, Mykrobe correctly identiﬁed the species as M. bovis and the strain as BCG
(Table 2). Ampliﬁcation with Phusion High-Fidelity master mix resulted in the highest
yield (760 Mb, with 68 coverage of BCG). All MinION experiments resulted in correct
identiﬁcation of the H57D mutation in pncA that confers pyrazinamide resistance in
TABLE 1 Yields from pure BCG and negative sputum spiked with BCG sequenced by
Illumina MiniSeq
Sample
Estimated no. of
fmol loaded
Yield
(Mb)
Read
length (bp)
Mean BCG coverage
depth (no. of reads)
Pure BCG TB1_N716 800 381 101 84.0
50% BCG TB1_N718 800 244 101 31.0
50% BCG TB1_N719 800 257 101 33.0
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BCG, but in the 5% spike, this call was ﬁltered out as it only had k-mer coverage of 1
on the resistant allele and did not achieve the required conﬁdence threshold. In all
cases, no false resistance calls were made, but deep coverage was needed to be able
to genotype all 175 mutations in the catalogue (see Table S3). Although the pure
BCG/R9 and 15% BCG/Phusion/R9 runs missed only 3/175 and 1/175 mutations, re-
spectively (Table 2), only the R9.4 sequencing run (below) allowed all of the mutations
to be typed.
With all ﬁve samples sequenced on R9 ﬂow cells, the data yield was highest at
the start of the run, with consistent yield proﬁles. For the Phusion/15% run, we
obtained 65% of the data in 8 h and 80% in 10 h (see Fig. S3). Despite the high
sequencing error rate (see Fig. S4), high-accuracy genotyping of known SNPs/indels
was achievable as described above.
Using two independent methods (see Materials and Methods), we measured a
strong bias in the distribution of SNP errors in the consensus of the MinION data. Both
methods agreed that the bias was systematic, consistent with a strong A-to-G error bias
within a 1D read (see Tables S4 and S5), but differed in their determination of the
strength of the bias (28% versus 50% A to G, respectively). A ﬁlter to ensure that SNP
calls have support from reads mapping to both strands could remove such errors.
Turnaround time of 12.5 h with ONT R9.4 MinION.We sequenced a single sample
(15% BCG-spiked, ZN-negative sputum) on the latest R9.4 MinION ﬂow cell (see
Materials and Methods). The yield was 1.3 Gb in 48 h. We were able to detect the M.
tuberculosis complex, identify the strain as BCG, detect the correct pyrazinamide
resistance mutation, and correctly place the sample on the phylogenetic tree after 1 h
of sequencing. After 3 h, 170 of 175 mutations were genotyped conﬁdently; after 4 h,
we had deﬁnitive results for all of the drugs except streptomycin; and after 6 h, we had
deﬁnitive results for streptomycin and could stop sequencing. One pyrazinamide
mutation remained ungenotyped, but since we already had a conﬁdent resistance call
for pyrazinamide, there would be no need to continue. Sufﬁcient coverage on the ﬁnal
mutation was obtained after a further 3 h (a total of 9 h of sequencing; Table 3).
Incorporating 6.5 h for decontamination, DNA extraction, and sample preparation (Fig.
5), this would give a turnaround time of 7.5 h for identiﬁcation of the species,
phylogenetic placement, and initial susceptibility predictions and 12.5 h for complete
results.
We took our phylogenetic placement of the MiniSeq BCG data as truth, four SNPs
distant from a BCG sample on the predeﬁned tree. After 1 h of sequencing with R9.4,
we were able to conﬁdently genotype 22,694 of the 68,695 SNPs, placing the sample
at the correct leaf of the tree, at an estimated distance of three SNPs. Thus, our
genotyping on 1D nanopore reads had, at most, seven errors (three plus four) out of
22,694 SNPs—an error rate below 0.03%.
Finally, on the basis of the performance of the 1.3-Gb R9.4 sequencing run, we
estimate (see Materials and Methods) that full susceptibility prediction would fail to be
generated for 17 of the 39 sputum samples sequenced here (MiSeq) with 8% M.
tuberculosis. However, for the 11/39 samples with 84% M. tuberculosis, species iden-
TABLE 2 Yields from pure BCG and negative sputum spiked with BCG both sequenced by the MinION 1D protocol
Model Sample
No. of
fmol
loaded
Read
count Yield/Mb
Avg read
length (kb)
Mean BCG
coverage depth
(no. of reads)
H57D R allele k-mer
coverage depth
(no. of k-mers)a
% of mutations
typed
(no. not typed)
R9 Pure cultured BCG NAb 297,239 360 1.2 80 17 99 (1)
R9 5% BCG LongAmp 82 182,670 559 2.0 19 1c 47 (93)
R9 10% BCG LongAmp 76 180,507 467 1.8 10 3 56 (77)
R9 15% BCG LongAmp 51 203,285 627 2.0 35 3 90 (18)
R9 15% BCG Phusion 27 184,895 758 2.4 68 10 98 (3)
R9.4 15% BCG Phusion 43 754,338 1,306 1.7 147 16 100 (0)
ak-mer coverage on resistance allele of the H57D mutation in pncA, known to be present in BCG.
bNA, data not available.
cResistance SNP detected but failed conﬁdence threshold and ﬁltered out.
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tiﬁcation and initial susceptibility predictions would be obtained within 20 min of
sequencing and full results would be obtained within 93 min (see Fig. S8 and Table S6).
Costing. The reagent costs (sample decontamination, extraction, sequencing library
preparation, and sequencing) per sample were £96 (MiSeq, 12 samples/run), £198
(MiniSeq, 3 samples/run), £515 (R9 MinION, 1 sample/run), and £101 to £172 (R9.4
MinION, between 3 and 5 samples/run [approximate cost, as a multiplexing kit is not
yet available]). See Table S7 for details.
DISCUSSION
Anticipating a growing knowledge base of the molecular determinants of antibiotic
resistance (1), we have developed a method of extracting and purifying mycobacterial
DNA from primary clinical samples and producing accurate sequence data in a clinically
useful time frame. We have demonstrated ﬁrst that direct WGS of sputum is possible
and gives genotypic DST predictions that are concordant with phenotype and
concordant phylogenetic placement with culture-based sequencing. Second, with
an Illumina MiSeq sequencer, we can obtain results within 48 h for a £100
consumable cost per sample. Using Illumina MiniSeq can deliver a same-day test
result (16 h) for an estimated consumable cost of £198 per sample. Although the costs
presented here only represent reagents, they are still likely to be below those of
traditional phenotyping (£518 to provide ﬁrst- and second-line DST and mycobacterial
interspersed repetitive unit-variable number of tandem repeats analysis in a bottom-up
costing including, for example, consumables, staff time, and overheads [16] versus £495
for MiSeq under the same costing model). The cost of MiSeq consumables is also well
below that of the SureSelect procedure (£203 per sample) (18).
The World Health Organization (WHO) has called for affordable and accessible
point-of-care TB diagnostics, including for DST. Current molecular assays provide partial
information on some drugs but do not easily scale to incorporate a growing list of
recognized resistance mutations. Furthermore, additional assays are currently needed
where surveillance or outbreak detection is indicated, at additional cost. A single assay
providing diagnostic information and data for surveillance and outbreak detection is
therefore an attractive prospect.
In cities where there are large numbers of TB cases (for example, upward of 65,000
TB cases per year in Mumbai), centralized sequencing services taking advantage of
high-throughput Illumina sequencing platforms may be applicable. However, at current
prices in 2017, the relatively high capital costs and the requirement for a well-equipped
laboratory are impediments to implementation across the full range of locations across
the world. For a complete solution, the ability to function in various low-tech environ-
ments is a practical necessity. The MinION can deliver this, at least on a small scale, as
demonstrated in Guinea last year during the Ebola outbreak (23). We conﬁrm here that,
despite the high error rate in reads, given deep coverage, it is possible to accurately
TABLE 3 Susceptibility prediction at time stamps during R9.4 run
Hr
% of AMR
mutations
typed
No. of mutations
ungenotyped
(total, 175) Ungenotyped mutation(s) Drug(s) awaiting results
1 57.1 75 —a All but pyrazinamide
2 88.5 20 katG S700, L141, V633, W191, D142, L704; gid L26, V41, G34, R47,
G117, A205, R118, Q125; rpoB H445; embB D328, G406; rpsL
K43; pncA T47, K48b
Isoniazid, streptomycin,
rifampin, ethambutol
3 97.1 5 embB D328; gid G34, A205; katG W191; pncA T47 Ethambutol, streptomycin,
isoniazid
4 98.2 3 gid G34, A205; pncA T47 Streptomycin
5 98.8 2 gid G34; pncA T47 Streptomycin
6–9 99.4 1 pncA T47
9 100 0
aUngenotyped mutations omitted because 75 is too many to list.
bFurther ungenotyped pncA mutations could be ignored, as H57D had already been detected at 1 h. The sample was already predicted to be pyrazinamide resistant;
thus, pyrazinamide is not listed.
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genotype resistance SNPs by the MinION method applied here. However, widespread
implementation would require much larger feasibility studies, similar to those recently
conducted to implement MiSeq sequencing from MGIT samples for Mycobacteria
diagnosis by Public Health England.
Since with Illumina technology the depth of sequencing is determined in advance
(by the number of isolates run in a batch), the small amount ofM. tuberculosis in a direct
sample can result in test failures. In this experiment, M. tuberculosis identiﬁcation and
susceptibility prediction failed in 2/39 and 13/37 samples, respectively. MinION se-
quencing, in theory, allows sequencing to continue until sufﬁcient coverage has been
obtained, giving faster results when there is a high load and avoiding this type of failure
when the load is low. The throughput obtained here with a 15% BCG-spiked sputum
sample and R9.4 ﬂow cells (1.3 Gb) would allow a turnaround time of 12.5 h (sample to
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FIG 5 Timelines. We compared the method of Brown et al. with the results of this study obtained with Illumina
MiSeq and MiniSeq and ONT MinION. We assumed that no step of the process can be initiated after 6 p.m. or before
8 a.m. The method of Brown et al. has a rapid extraction step but also a 20-h overnight enrichment step, resulting
in a 50-h turnaround time. In our study, we did 27-h MiSeq runs (paired 150-bp reads), but since Mykrobe is k-mer
based, a 16-h run (paired 75-bp reads) would give equivalent results; we therefore display that potential timeline
here. The DNA extraction process was updated for the MiniSeq and MinION experiments, removing the ethanol
precipitation step. In normal use, this would take 3 h. The 1.5-h orange rectangle on the MinION time lines includes
both PCR and the 10-min sample preparation step. In this experiment, since we used spiked BCG DNA in sputum,
we did not use a human depletion step, thus taking only 2 h. This image is intended to show comparable real-use
time lines, and so the MiniSeq/MinION time lines are shown with 3-h extraction steps. MiniSeq enables a 16-h
turnaround time by sequencing for only 7 h. R9 MinION also delivers sub-24-h results but requires one ﬂow cell per
sample. R9.4 MinION gives a 12.5-h turnaround time (6 h of sequencing with real-time [i.e., simultaneous] base
calling when used on a single sample).
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complete results) or only 7.5 h to detection of M. tuberculosis and pyrazinamide
resistance and placement on a phylogenetic tree.
We have predicted that identiﬁcation to the species level and initial DST could be
generated after 20 min (mean) of sequencing with MinION R9.4 and ﬁnal DST within
150 min, providing the M. tuberculosis concentrations are sufﬁcient (20% of the
sequencing reads in this study). For these samples, it would be possible to multiplex
sequencing and reduce per-sample costs. Conversely, for samples with low M. tuber-
culosis concentrations, nanopore sequencing would not provide sufﬁcient data within
48 h. Although these predictions are based on a single R9.4 sequencing run, the data
demonstrate clear scope for technology-driven improvement through improved my-
cobacterial enrichment and/or nonmycobacterial DNA depletion (Fig. 2a), higher se-
quencing yield, or real-time ﬁltering of contamination (24).
Were this methodology implemented in clinical practice, we would expect a portion
of direct sample to be retained for culture in all cases; this would be available for
resequencing in case of insufﬁcient sequencing depth and would allow distinction
between live and dead bacilli. Unlike our study, where we had to use sample discards
after clinical processing, if implemented, the increased sample volume could be used
for sequencing closer to the time the sample was taken, presumably with greater
success. Both Illumina and ONT technologies would require some level of sample
batching, but for both, the turnaround time is likely to be much shorter than that of
traditional phenotyping and could challenge same-day molecular tests such as Xpert
MTB/RIF.
In conclusion, diagnostic and surveillance information can now be obtained directly
from patient specimens in 16/44 h with the Illumina MiniSeq and MiSeq platforms, a
considerable step forward. In addition, the ONT sequencing platform may offer the
same information in as little as 7 to 12.5 h. Faster and more automated sample
processing, as well as cost reductions, are clearly needed for adoption in low-income
settings. Achieving this would revolutionize the management of TB.
MATERIALS AND METHODS
Sample selection and processing. The ZN-positive direct respiratory samples with AFB scorings
of 1 to 3 used in this study had been originally collected from patients with subsequently conﬁrmed
M. tuberculosis infections at the John Radcliffe Hospital, Oxford Universities NHS Foundation Trust,
Oxford, United Kingdom (n  18), and Birmingham Heartlands Hospital NHS Foundation Trust, Birming-
ham, United Kingdom (n  22). Two of the 18 Oxford samples were culture-negative specimens taken
2.5 months apart from the same patient undergoing treatment for M. tuberculosis infection. If available,
corresponding MGIT cultures were collected for each direct sample (Oxford, n 11; Birmingham, n 17).
Two ZN- and culture-negative direct respiratory samples were also collected from the John Radcliffe
Hospital.
The discarded direct samples were collected only after sufﬁcient material had been obtained for the
routine diagnostic work ﬂow, including the requirement to ensure that enough sample volume remained
if reculture was requested. Consequently, study samples were of lower volume and quality than would
be the case if the method were used routinely. While waiting for the routine laboratory results, samples
were stored at4°C and later processed in batches of 5 to 12. All ZN-positive samples were digested and
decontaminated with the NAC-PAC RED kit (AlphaTec, USA). Direct samples and corresponding MGIT
culture aliquots (1 ml) were heat inactivated in a thermal block after sonication (20 min, 35 kHz) for 30
min and 2 h at 95C, respectively. MGITs were inactivated for 2 h owing to their heavy bacterial load.
Before DNA extraction, samples were stored at 4°C.
DNA extraction and Illumina MiSeq sequencing. Mycobacterial DNA was extracted from MGIT
cultures by a previously validated ethanol precipitation method (19). DNA was extracted from ZN-
positive direct samples by a modiﬁed version of this protocol. These modiﬁcations included a saline wash
followed by MolYsis Basic5 kit (Molzym, Germany) treatment for the removal of human DNA and addition
of GlycoBlue coprecipitant (Life Technologies, USA) to the ethanol precipitation step (see Fig. S5).
Libraries were prepared for MiSeq Illumina sequencing by using a modiﬁed Illumina Nextera XT
protocol (19). Samples were sequenced with the MiSeq Reagent kit v2, 2  150 bp in batches of 9 to 12
per ﬂow cell. The median library size (TapeStation; Agilent, USA) was 627 bp (IQR, 495 to 681 bp). The
median number of reads available per sample was 3.2 million (IQR, 2.8 to 4.1 million); this would yield
a median depth of approximately 213, given pure M. tuberculosis, although in this study, we anticipated
that nonmycobacterial reads would be present.
DNA extraction for ONT MinION and Illumina MiniSeq sequencing. ZN- and culture-negative
sputum and BCG (Pasteur strain; cultivated at 37°C in MGIT tubes) DNA was extracted by a modiﬁed
version of the method described in reference 19. Brieﬂy, following a saline wash, samples were
resuspended in 100 l of molecular-grade water and subjected to three rounds of bead-beating at 6 m/s
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for 40 s. The beads were pelleted by centrifugation at 16,100  g for 10 min, and 50 l of supernatant
was cleaned with 1.8 volumes of AMPure beads (Beckman Coulter, United Kingdom). Samples were
eluted in 25 l of molecular-grade water and quantiﬁed with a Qubit ﬂuorimeter (Thermo Fisher
Scientiﬁc, USA) (steps I, III, V, and VI of the MiSeq protocol [see Fig. S5]).
MiniSeq sequencing. Extracted ZN-negative sputum DNA and pure BCG DNA were combined in a
50:50 ratio (0.5 ng of each), and libraries were prepared alongside pure BCG DNA (1 ng) by using a
modiﬁed Illumina Nextera XT protocol (19). BCG and two BCG-sputum DNA samples were sequenced at
Illumina Cambridge Ltd., United Kingdom, with a Mid Output kit (FC-420-1004) reading 15 tiles and with
101 cycles.
MinION sequencing. All MinION sequencing utilized the best available sample preparation kit for
our samples and ﬂow cells (R9/R9.4 ﬂow cells and PCR-based sample preparation, as described below).
A single ZN-negative sputum extract was divided into three equal-concentration aliquots (187 ng), and
BCG DNA was added at 5, 10, and 15% of the total sputum DNA concentration. These 5 to 15% spikes
represent the lower end of the spectrum seen in the MiSeq samples described above (see Fig. 2a). These
samples, along with pure BCG DNA, were prepared in accordance with ONTs PCR-based protocol for
low-input libraries (DP006_revB_14Aug2015), with modiﬁed primers supplied by ONT, a 20-ng DNA input
into the PCR, and LongAmp Taq 2 master mix (New England BioLabs, USA). The PCR conditions used
were as follows: initial denaturation at 95°C for 3 min; 18 cycles of 95°C for 15 s, 62°C for 15 s, and 65°C
for 2.5 min; and a ﬁnal extension at 65°C for 5 min. Samples were cleaned in 0.4 volume AMPure beads,
and the PCR product was assessed with a Qubit ﬂuorimeter and TapeStation (Agilent, United Kingdom).
The ﬁnal elution was into 10 l of 50 mM NaCl–10 mM Tris HCl, pH 8.0. Finally, 1 l of PCR-Rapid Adapter
(PCR-RAD; supplied by ONT) was added and samples were incubated for 5 min at room temperature to
generate a presequencing mixture. The presequencing mixture was prepared for loading onto ﬂow cells
in accordance with standard ONT protocols, by using a loading amount of 50 to 100 fmol.
With the 15% BCG-spiked sputum DNA prepared as described above, ampliﬁcation was repeated by
using Phusion High-Fidelity PCR master mix with dimethyl sulfoxide (DMSO) (New England BioLabs, USA).
Gradient PCR was performed to identify the optimal annealing temperature for recovery of BCG DNA
(data not shown). The ﬁnal PCR conditions were as follows: initial denaturation at 98°C for 30s; 18 cycles
of 98°C for 10 s, 59°C for 15 s, and 72°C for 1.5 min; and a ﬁnal extension of 72°C for 10 min. Following
PCR, the sample was prepared for sequencing as described above. The ﬁnal loading amount was
approximately 27 fmol.
The above-described samples were sequenced with R9 spot-on generation ﬂow cells and the 48-h
protocol for FLO-MIN105 (ONT, United Kingdom). Base calling was performed via the Metrichor EPI2ME
service (ONT, United Kingdom) with the 1D RNN for SQK-RAD001 v1.107 work ﬂow.
Subsequently, a new 15% BCG-spiked sputum sample was prepared as described above, by using
Phusion master mix with DMSO. Sequencing was performed with R9.4 spot-on generation ﬂow cells and
the 48-h FLO-MIN106 protocol (ONT, United Kingdom). The ﬁnal loading amount was 43 fmol. Base
calling was performed after sequencing was complete with Albacore (ONT, United Kingdom), as base
calling via Metrichor failed. Subsequent tests of other samples (data not shown) showed that base calling
could have been performed in real time during the run.
Bioinformatic analysis of Illumina data. To determine levels of contamination and M. tuberculosis
in samples, reads were immediately mapped with bwa_mem (25) to the human reference genome
GRCh37 (hg19) and human reads were counted and permanently discarded. The remaining stored reads
were then mapped to the M. tuberculosis H37Rv reference strain (GenBank NC_018143.2), and any
unmapped reads were then mapped to nasal, oral, and mouth ﬂora available in the NIH Human
Microbiome Project database (http://www.hmpdacc.org/).
Mycobacterial species and antibiotic resistance to isoniazid, rifampin, ethambutol, pyrazinamide,
streptomycin, aminoglycosides (including capreomycin, amikacin, and kanamycin), and ﬂuoroquinolones
(including moxiﬂoxacin, oﬂoxacin, and ciproﬂoxacin) was predicted with Mykrobe predictor software (26)
v0.3.5, updated with a new validated catalogue of resistance-conferring genetic mutations (see Table S3;
from reference 1). For samples where the estimated depth of k-mer coverage of M. tuberculosis reported
by Mykrobe predictor fell below 3, no resistance predictions were made. The precise command used
was mykrobe predict SAMPLE_ID tb -1 FASTQ –panel walker-2015 –min-depth 3.
Phylogenetic analysis of pairs. Conservative SNP calls were made with Cortex (27) (independent
work ﬂow, k  31) on 3,480 samples from reference 1. Singleton variants were discarded, and a
deduplicated list of 68,695 SNPs was constructed. All samples (from our study and from reference 1) were
genotyped at these sites by using the Mykrobe predictor genotyping model (26). All 27 of the MGIT
samples had high coverage, but several of the direct samples had low coverage (Fig. 3a, bottom left). For
this comparison, we excluded pairs where the direct sample had 5 coverage to ensure like-with-like
analysis, leaving 17 pairs. We then measured the number of SNP differences between the paired direct
and MGIT samples, counting only sites where both genotypes had high conﬁdence in our Illumina model
(difference between log likelihood of called genotype [e.g., ALT allele] and log likelihood of uncalled
genotype [e.g., REF allele] of 1), and neither site was called as heterozygous.
Samples were placed on the phylogenetic tree of 3,480 samples from reference 1 by identifying the
leaf with the fewest SNP differences across the 68,695 sites. Placement therefore returns a closest leaf
and a SNP distance to that leaf.
Statistical analysis. Univariable and multivariable linear regression was used to identify indepen-
dent factors affecting the log10 DNA concentration after extraction. Analyses were performed with Stata
14.1 (2015; StataCorp, USA).
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Bioinformatic analysis of MinION data. Mykrobe predictor version v0.5.0-6-g6b19d83 was used to
predict resistance from the MinION base called reads (command: mykrobe predict SAMPLE_ID tb 1
FASTQ –panel walker-2015 –ont). This uses an ONT-speciﬁc genotyping model, a modiﬁcation of that
published in reference 26. Speciﬁcally, it uses a Poisson model of total k-mer counts on alternate alleles
(instead of using the median k-mer coverage) and applies a “genotype conﬁdence” threshold of 100
(difference between log likelihood of called genotype (e.g., ALT allele) and that of uncalled genotype
(e.g., REF allele) of 100). Figures S6 and S7 show the genotype conﬁdence distribution split by whether
the genotype is correct or not.
Yield and timing were analyzed with Poretools (28). For the R9.4 sample, Mykrobe predictor was
applied to the cumulative read output at each hour. The yield of BCG was measured by mapping to a
BCG reference (accession no. BX248333.1).
Phylogenetic placement of the 15% spike BCG sample sequenced on MinION R9.4 was achieved as
for the Illumina data—by genotyping 68,695 SNPs and choosing the leaf with the fewest SNP differences
across those sites.
MinION error analysis. Error bias in the consensus of MinION R9 1D pure BCG reads was measured
in two ways by using reads from the pure BCG sequencing run described above. By method 1, reads were
mapped to the M. tuberculosis reference genome by using bwa_mem, and then this was passed to the
consensus tool racon (29). The output of this was compared with the BCG reference genome with
MUMMER (30). Since we were comparing M. bovis BCG with its own reference genome, any observed
SNPs were due either to sequencing errors or to evolution since the reference genome was constructed.
We assumed that the latter were negligible in comparison with the error rate in nanopore reads (see Fig.
S4) and considered all SNPs to be errors. Bias in these errors was observed by looking at isolated SNPs
(avoiding alignment artifacts due to nearby indels). The results are shown in Table S4. By method 2, de
novo assembly was performed with Canu (31), and then this was compared with the BCG reference
genome with MUMMER as described above. The results are shown in Table S5.
The mapping approach (method 1 described above) found that 28% of the consensus errors were A
to G and 60% were T to C. (Note that these refer to the SNP with respect to the reference and not to
errors within a single read passing through a pore.) The de novo assembly approach found that 50% of
the consensus errors were A to G and 44% were T to C. Although the estimates differed quantitatively,
they agreed on the existence and direction of the bias.
MinION turnaround estimates obtained with empirical M. tuberculosis read proportion data.
The proportion of M. tuberculosis reads found in our clinical samples varied over a considerable range
(Fig. 2a, blue), with 0.3 to 97.9% of the sequenced DNA coming from M. tuberculosis. To model how this
distribution might translate into MinION performance, we used hourly time stamps on the R9.4 MinION
total DNA yield curve (see Fig. S3) and coverage needed to detect M. tuberculosis, pyrazinamide
resistance, and full susceptibility results to estimate the turnaround times for all Illumina-sequenced
samples, supposing that they all were to yield 1.3 Gb of MinION reads with the same proportion of reads
from M. tuberculosis as seen in Fig. 2a. The results are displayed in Fig. S8 and Table S6, with samples
ordered by increasing proportions of M. tuberculosis.
Costing analysis. Basic costing included reagents required for sample decontamination, DNA
extraction, MiSeq and Nanopore library preparation, and sequencing (correct as of November 2016).
Generic laboratory consumables (e.g., pipette tips, tubes) were not included. SureSelect (Agilent, United
Kingdom) costs, as used by Brown et al. (18), were obtained via a company representative and were
correct of June 2016. U.S. dollars were converted to Great British pounds (GBP) at $1.25/GBP. See Table
S7 for details.
Ethics. For this study, no ethical review was required because it was a laboratory method develop-
ment study focusing on bacterial DNA extracted from discarded samples identiﬁed only by laboratory
numbers with no personal or clinical data. Sequencing reads identiﬁed as human on the basis of fast
mapping with BWA were counted and immediately permanently discarded (i.e., never stored electron-
ically).
Accession number(s). The MiSeq, MiniSeq, and MinION data obtained in this study have been
deposited in the NCBI Sequence Read Archive under study accession number SRP093599.
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